Pacific Edge Ltd
Pacific Edge Limited is a global cancer diagnostics company.
The business
Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.
Small Caps Research
No research on Pacific Edge Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise PEB based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Pacific Edge Test Volumes Rise 2.7% in Q4 on Payer Expansion
Pacific Edge (PEB) Q4 test volumes rise 2.7% on payer expansion; eyes Medicare LCD draft by Sept 2026 as coverage broadens, signaling regulatory momentum.
Pacific Edge’s Cxbladder Triage biomarker test recognised as standard of care in AUA guideline update
New Zealand-based cancer diagnostics company Pacific Edge (ASX: PEB) has had its Cxbladder Triage test included as a standard of care by the American Urological Association (AUA). In a major amendment to the 2020 AUA microhematuria guideline, the AUA panel has incorporated language for the use of urine-based biomarkers for intermediate-risk patients. Most notably, it […]
Medtech firms assessing impact of proposed FDA regulation changes
Local medtech companies are rushing to assess proposed new US Food and Drug Administration (FDA) rule changes that seek to have laboratory developed tests (LDTs) regulated as medical devices under the US Federal Food, Drug, and Cosmetic Act. The proposed changes are being aggressively opposed by numerous associations including the Coalition for 21st Century Medicine […]
Market wrap: good news on jobs turns to bad news for shares
Once again, the Australian share market turned good economic news into a bad share performance as the ASX 200 index slumped to a three-month low of just 7042.3 points. Hot US jobs figures from ADP Research found that employers added 497,000 jobs in June – nearly double what was expected – driving most traders to […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.